Physician profile
Christopher J Russo
NPI 1639372345
$1,065.02
in general payments reported to CMS, 2019-2025
12 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $339 · 2021: $14.74 · 2023: $214 · 2024: $233 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $450.69 | 2020-2025 | Rocklatan, Clareon |
| Bausch & Lomb Americas INC. | $173.25 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $164.15 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $62.44 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $54.80 | 2019-2023 | |
| Nuvasive, INC. | $39.27 | 2019 | |
| Oyster Point Pharma, INC. | $33.10 | 2024 | Ryzumvi, Tyrvaya |
| Abbvie INC. | $21.78 | 2023 | Alphagan P, Lumigan |
| Thea Pharma INC. | $19.02 | 2024 | Iyuzeh |
| Shire North American Group INC | $18.23 | 2019 | |
| Harrow Eye, LLC | $15.24 | 2024 | Vevye |
| Allergan, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.